Send to

Choose Destination
Curr Drug Targets. 2019;20(9):938-941. doi: 10.2174/1389450120666190308111619.

Trans-sialidase Associated with Atherosclerosis: Defining the Identity of a Key Enzyme Involved in the Pathology.

Author information

Department of Genetics, Cytology and Bioengineering, Faculty of Biology and Medicine, Voronezh State University, Voronezh, Russian Federation.
Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russian Federation.
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 109240 Moscow, Russian Federation.
Institute for Atherosclerosis Research, Skolkovo Innovative Center, 121609 Moscow, Russian Federation.
Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.


Atherosclerosis is associated with the increased trans-sialidase activity, which can be detected in the blood plasma of atherosclerosis patients. The likely involvement in the disease pathogenesis made this activity an interesting research subject and the enzyme that may perform such activity was isolated and characterized in terms of substrate specificity and enzymatic properties. It was found that the enzyme has distinct optimum pH values, and its activity was enhanced by the presence of Ca2+ ions. Most importantly, the enzyme was able to cause atherogenic modification of lowdensity lipoprotein (LDL) particles in vitro. However, the identity of the discovered enzyme remained to be defined. Currently, sialyltransferases, mainly ST6Gal I, are regarded as major contributors to sialic acid metabolism in human blood. In this mini-review, we discuss the possibility that atherosclerosis- associated trans-sialidase does, in fact, belong to the sialyltransferases family.


Trans-sialidase; atherosclerosis; blood plasma; circulation; sialic acid; sialyltransferase.

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center